Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IKT 
Inhibikase Therapeutics Inc (IKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: IKT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -30.38% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 173.71M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 143319 | Beta 1.05 | 52 Weeks Range 1.12 - 4.20 | Updated Date 04/6/2025 |
52 Weeks Range 1.12 - 4.20 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.09 |
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate - | Actual -0.1749 |
Profitability
Profit Margin - | Operating Margin (TTM) -99999999.99% |
Management Effectiveness
Return on Assets (TTM) -112.68% | Return on Equity (TTM) -270.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39355422 | Price to Sales(TTM) 1000000 |
Enterprise Value 39355422 | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 2.75 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 72681800 | Shares Floating 16663085 |
Shares Outstanding 72681800 | Shares Floating 16663085 | ||
Percent Insiders 12.35 | Percent Institutions 76.05 |
Analyst Ratings
Rating 4.33 | Target Price 7 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inhibikase Therapeutics Inc
Company Overview
History and Background
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2007. It focuses on developing therapeutics for Parkinson's disease and related disorders by inhibiting protein misfolding and aggregation.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Development of small molecule therapeutics targeting protein misfolding in neurodegenerative diseases, primarily Parkinson's disease.
Leadership and Structure
The company is led by a management team with experience in drug development and neuroscience. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Risuzinanim: Risuzinanim is Inhibikase Therapeutics' lead drug candidate for the treatment of Parkinson's disease and related Lewy body disorders. It's currently in clinical trials. Market share data and revenue figures are not yet available as the product is in development. Competitors include companies developing therapies for Parkinson's disease, such as those targeting LRRK2 or alpha-synuclein.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and subject to regulatory changes. The market for Parkinson's disease therapeutics is growing due to the increasing prevalence of the disease and advancements in treatment options.
Positioning
Inhibikase Therapeutics is positioning itself as a leader in developing disease-modifying therapies for Parkinson's disease by targeting protein misfolding. Its competitive advantage lies in its unique mechanism of action.
Total Addressable Market (TAM)
The Parkinson's disease therapeutics market is estimated to be worth billions of dollars. Inhibikase Therapeutics is positioned to capture a significant share of this market if its drug candidate is successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action targeting protein misfolding
- Lead drug candidate in clinical trials
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other neurodegenerative diseases
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- TEVA
- ABBV
- GILD
Competitive Landscape
Inhibikase Therapeutics faces competition from established pharmaceutical companies with greater financial resources and established market presence. Its competitive advantage lies in its novel mechanism of action.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its drug candidate through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval. Analyst estimates vary widely due to the inherent uncertainty of drug development.
Recent Initiatives: Recent initiatives include ongoing clinical trials of risuzinanim and efforts to secure funding for further development.
Summary
Inhibikase Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing novel therapies for Parkinson's disease. Its strengths lie in its unique approach and experienced management, but it faces significant challenges including limited financial resources and the inherent risks of drug development. Successful clinical trials are critical for its future growth. Investors should monitor clinical trial results and funding activities closely. They have no Acquisitions to date.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies involves significant risks, including the risk of drug development failure.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibikase Therapeutics Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2020-12-23 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.inhibikase.com |
Full time employees 15 | Website https://www.inhibikase.com | ||
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.